ADReCS

Pharmaceutical Information

Drug Name	Ropivacaine
Drug ID	BADD_D02416
Description	Ropivacaine is an aminoamide local anaesthetic drug commonly marketed by AstraZeneca under the trade name Naropin. It is present as a racemic mixture of the enantiomers containing equal proportions of the “S” and “R” forms. The marketed form contains the single S-enantiomer as the active ingredient.
Indications and Usage	Used in obstetric anesthesia and regional anesthesia for surgery.
Marketing Status	approved
ATC Code	N01BB09
DrugBank ID	DB00296
KEGG ID	D08490
MeSH ID	D000077212
PubChem ID	175805
TTD Drug ID	D09RHQ
NDC Product Code	76339-126; 29902-0022
UNII	7IO5LYA57N
Synonyms	Ropivacaine \| 1-Propyl-2',6'-pipecoloxylidide \| 1 Propyl 2',6' pipecoloxylidide \| Naropin \| Ropivacaine Monohydrochloride \| Ropivacaine Hydrochloride \| AL 381 \| AL-381 \| AL381 \| Naropeine \| LEA 103 \| LEA-103 \| LEA103 \| Ropivacaine Monohydrochloride, (S)-isomer

Chemical Information

Molecular Formula	C17H26N2O
CAS Registry Number	84057-95-4
SMILES	CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Anaphylactic reaction	24.06.03.006; 10.01.07.001	0.000179%
Anaphylactic shock	24.06.02.004; 10.01.07.002	0.000179%		Not Available
Aphonia	19.19.01.002; 17.02.08.009; 22.12.03.001	0.000179%
Apnoea	22.02.01.001	0.000179%
Arthropathy	15.01.01.003	0.005037%		Not Available
Atrial tachycardia	02.03.03.004	0.000179%
Blindness	06.02.10.003; 17.17.01.003	0.000179%		Not Available
Bradycardia	02.03.02.002	0.000447%		Not Available
Cardiac arrest	02.03.04.001	0.001018%
Cardiogenic shock	24.06.02.006; 02.05.01.003	0.000179%		Not Available
Chest pain	22.12.02.003; 08.01.08.002; 02.02.02.011	0.000179%		Not Available
Circulatory collapse	24.06.02.001	0.000179%		Not Available
Coma	17.02.09.001	0.000179%		Not Available
Cyanosis	22.02.02.007; 23.06.04.005; 02.11.04.004; 24.03.01.007	0.000179%
Diaphragmatic paralysis	22.09.02.002; 17.01.04.014	0.000179%		Not Available
Diplegia	17.01.04.015	0.000179%		Not Available
Drug ineffective	08.06.01.006	0.023221%		Not Available
Dysgeusia	17.02.07.003; 07.14.03.001	0.001000%
Dyskinesia	17.01.02.006	0.001608%
Dysphoria	19.04.02.004	0.000179%		Not Available
Dyspnoea	02.11.05.003; 22.02.01.004	0.000714%
Generalised tonic-clonic seizure	17.12.01.002	0.000536%		Not Available
Horner's syndrome	17.05.01.004; 16.32.03.006; 06.09.04.002	0.000179%		Not Available
Hypoaesthesia	23.03.03.081; 17.02.06.023	0.006216%		Not Available
Hypotension	24.06.03.002	0.000357%
Hypoxia	22.02.02.003	0.000179%
Loss of consciousness	17.02.04.004	0.000357%		Not Available
Movement disorder	17.01.02.010	0.004519%		Not Available
Muscular weakness	17.05.03.005; 15.05.06.001	0.000875%
Nervous system disorder	17.02.10.001	0.000179%		Not Available

The 1th Page 1 2 Next Last Total 2 Pages